DEFENSE HEALTH AGENCY DHA USA Tender

The Defense Health Agency (dha), Northeastern Healthcare Operations Contracting Division (neho-cd), On Behalf Of At. Augusta Military Medical Center, In Support Of The Pathology Department, Anatomic Section’s Requirement For A Source That Provides Testing For Prognosis And Prediction Of Chemotherapy. The Testing Services Are Needed To Conduct Genetic Molecular Analysis To Deliver Relevant, Diagnostic Genetic And/or Biological Tumor Information That Enables Ordering Healthcare Providers To Optimize Treatment Protocols Regarding Potential Breast, Colon And Prostate Cancer Types. The Oncotype Dx ® Test Is Identified As The Only Multigene Assay That Is Both Predictive Of Chemotherapy Treatment Effect And Prognostic Of Disease Outcome. As Such, This Office Intends To Award A Firm Fixed Price Contract On A Sole Source Basis To Genomic Health, Inc, 301 Penobscot Drive Redwood City Ca 94063-4700, Cage: 37am2. however, If Your Company Possesses The Ability To Provide A Multigene Assay That Is Both Predictive Of Chemotherapy Treatment Effect And Prognostic Of Disease Outcome, Provide This Office With Your Company’s Substantiated And Validated Information For Further Consideration.